Table 3 Adjuvant treatments received by patients eligible for adjuvant abemaciclib, adjuvant ribociclib, and by patients non-eligible for adjuvant CDK4/6
Characteristics | Eligible for adjuvant ribociclib (N = 1068) | Eligible for adjuvant abemaciclib (N = 440) | Not eligible for any CDK4/6 inhibitor (N = 2031) | Overall population (N = 3103) | ||||
|---|---|---|---|---|---|---|---|---|
N | (%) | N | (%) | N | (%) | N | (%) | |
Chemotherapy | ||||||||
Yes. adjuvant | 607 | 57.1 | 272 | 62.2 | 228 | 11.2 | 837 | 27.1 |
Yes. neoadjuvant | 99 | 9.3 | 58 | 13.3 | 58 | 2.9 | 158 | 5.1 |
Yes. both | 16 | 1.5 | 12 | 2.8 | 3 | 0.2 | 19 | 0.6 |
No | 342 | 32.1 | 95 | 21.7 | 1737 | 85.7 | 2080 | 67.2 |
Unknown | 4 | 3 | 5 | 9 | ||||
Endocrine therapy | ||||||||
Yes. adjuvant | 1012 | 95.1 | 415 | 95.0 | 1481 | 73.1 | 2497 | 80.7 |
Yes neoadjuvant and adjuvant | 12 | 1.1 | 5 | 1.1 | 12 | 0.6 | 24 | 0.8 |
No | 40 | 3.8 | 17 | 3.9 | 534 | 26.3 | 574 | 18.5 |
Unknown | 4 | 3 | 4 | 8 | ||||
Radioth−erapy | ||||||||
Yes | 972 | 91.4 | 414 | 94.7 | 1706 | 84.2 | 2682 | 86.7 |
No | 92 | 8.6 | 23 | 5.3 | 321 | 15.8 | 413 | 13.3 |
Unknown | 4 | 3 | 4 | 8 | ||||
